Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-01
DOI
10.1038/s41375-020-0809-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
- (2019) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- ZAP-70 in chronic lymphocytic leukemia: A meta-analysis
- (2018) Yini Liu et al. CLINICA CHIMICA ACTA
- Immunomodulatory effects of CD38-targeting antibodies
- (2018) Niels W.C.J. van de Donk IMMUNOLOGY LETTERS
- A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
- (2017) Mary E. Matyskiela et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28– T-cells
- (2017) Brigitte Neuber et al. Oncotarget
- Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
- (2017) Gianfranco Pittari et al. Frontiers in Immunology
- The Rapid Evolution of Novel Therapies in Multiple Myeloma
- (2016) Kenneth C. Anderson Journal of the National Comprehensive Cancer Network
- Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
- (2015) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- K33-linked polyubiquitination of Zap70 by Nrdp1 controls CD8+ T cell activation
- (2015) Mingjin Yang et al. NATURE IMMUNOLOGY
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
- (2012) J. Richter et al. BLOOD
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- ZAP-70: An Essential Kinase in T-cell Signaling
- (2010) H. Wang et al. Cold Spring Harbor Perspectives in Biology
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now